Deep in one of the more passionate and hyperbolic corners of the internet exists a community of investing subReddits. What once existed as a public forum for discussing stock prospects and company valuations has now evolved into several different pockets of speculative fervor. After all, it's very exciting to get together with strangers on the internet and speculate how high your portfolio of meme stocks or penny stocks can go. That being said, it's important to keep in mind that, no matter how often an inv ...

Drilling into the Short Squeeze Opportunity Trade of the Day: Buy CUTR Stock in the Open Market Yes, the aforementioned one-year drop of over 88% is worrying. Nevertheless, since November 2023, CUTR stock has "relatively" stabilized. It also appears that there's a reversion to the mean roughly around the $2 price. That's a big positive since it's a psychologically significant milestone. With a rough baseline established, the idea here is to set up camp before a potential bull wave materializes. Given the ex ...

SAN FRANCISCO, May 21, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Cutera, Inc. investors that the firm is investigating potential legal claims arising from recent accounting issues, a restatement of the company's financials, and other potential wrongdoing. Current shareholders are encouraged to contact the firm regarding their rights. On November 8, 2023, Cutera announced that it would delay filing its quarterly financial results for the third quarter of 2023 "pending resolution of an issue ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 000-50644 Cutera, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0492262 (St ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K trademark ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 000-50644 CUTERA, INC. (Exact name of registrant as specified in its charter) Delaware 77-0492262 (State or other ...

Company Participants Operator I would now like to turn the conference over to Greg Barker, Vice President of Finance and Investor Relations. Please go ahead. Thank you, operator, and thank you, everyone, for joining us. With me today is Taylor Harris, Cutera's Chief Executive Officer; and Stuart Drummond, Interim CFO. Following our prepared remarks, we'll take your questions. Forward-looking statements include, among others, statements regarding financial guidance, regulatory approvals, productivity improve ...

Cutera (CUTR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.42%. A quarter ago, it was expected that this maker of laser skin treatments would post a loss of $0.91 per share when it actually produced a loss of $1.36, delivering a surprise of -49.45%.Over the last four quarters, the compan ...

Exhibit 99.1 BRISBANE, California, May 9, 2024 ─ Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2024. "I am pleased with our progress in the first quarter of 2024, highlighted by a strong sequential gain in our AviClear revenue, as well as improvement in our gross margin relative to the second half of 2023, reflecting our clear focus on building a culture of operational ...

Financial Data and Key Metrics - Total revenue for Q4 2023 was $49.5 million, a 26% decrease from $67.4 million in Q4 2022, primarily due to a $14 million decline in capital equipment revenue [21][49] - Non-GAAP gross profit for Q4 2023 was $9.9 million with a gross margin rate of 20%, compared to 59.4% in Q4 2022, driven by a 19 percentage point impact from increased inventory reserves [22] - Non-GAAP operating loss for Q4 2023 was $26.1 million, compared to an operating income of $0.2 million in Q4 2022 [52] - Cash and cash equivalents decreased by $36 million sequentially to $143.6 million at the end of Q4 2023, primarily due to a net loss of $28 million and working capital changes [24] Business Line Data and Key Metrics - AviClear revenue was stable at $3.9 million in Q4 2023, with capital revenue from the enhanced product offering offsetting a decline in treatment revenue [7][50] - International business improved sequentially from Q3 to Q4 2023, while North American business experienced a modest sequential decline [7] - Utilization rates at dermatology practices are approximately 50% higher than other specialties, with dermatologists being a disproportionate percentage of the most successful accounts [8] Market Data and Key Metrics - International markets showed strength in capital equipment sales and skincare, contributing to the sequential revenue increase from Q3 to Q4 2023 [49] - The company expects international markets to contribute around 55% of revenue in 2024, similar to 2023, with direct businesses in major European markets, Japan, and Australia [74][93] Company Strategy and Industry Competition - The company is focused on operational excellence, building a global AviClear franchise, and driving long-term profitability [39] - A new business model for AviClear offers greater flexibility, including a hardware and software upgrade and a shift from a per-patient model to paying for individual treatments [14] - The company plans to launch a refreshed product platform in 2024 and is conducting pilot studies on expanded indications for AviClear, such as sebaceous hyperplasia and hidradenitis suppurativa [46][64] Management Commentary on Operating Environment and Future Outlook - Management noted stabilization in the business in Q4 2023, with better-than-expected revenue and cash burn results [35] - The company expects to consume cash more heavily in the first half of 2024 due to supply obligations related to AviClear, with a projected cash balance of $55 million to $60 million at the end of 2024 [25] - Management remains cautious about the macroeconomic environment but is optimistic about improving operational efficiency and gross margins over time [9][86] Other Important Information - The company has completed a global restructuring program, reducing headcount by close to 25%, leading to annualized personnel-related savings of over $20 million [18] - Cutera Academy, a two-day training program, will launch in April 2024 to support customer growth and utilization of AviClear [15] - The company has transitioned AviClear and excel V+ manufacturing in-house, improving quality and reducing costs [13][102] Q&A Session Summary Question: Revenue guidance breakdown for 2024 - Revenue guidance for 2024 is $160 million to $170 million, including $4 million of skincare revenue in Q1, with systems and consumables revenue expected to be slightly down year-over-year [25][56] Question: Cash burn and inventory management - Cash burn in 2024 will be heavily weighted towards the first half, with inventory expected to become a cash tailwind in the second half as the company works down excess inventory [57][58] Question: AviClear procedural revenue and international launch learnings - AviClear procedural revenue was impacted by dormant accounts, with 55% of the account base not performing procedures in Q4 2023 [30] - International launch learnings indicate that disciplined, methodical market entry and strong customer support are key to building successful AviClear practices [62][84] Question: New product launches and expanded indications for AviClear - The company plans to launch a refreshed product platform in 2024 and is exploring expanded indications for AviClear, including sebaceous hyperplasia and hidradenitis suppurativa [46][64] Question: Rep productivity and field organization expansion - Rep productivity has remained consistent, with plans to increase the North American field organization by adding 15 or more capital reps and expanding the key account manager (CAM) team to 25 [88][89] Question: Convertible debt maturities - The company has three tranches of convertible debt, with the first maturity in March 2026 ($70 million face value), and is focused on addressing its capital structure after advancing key AviClear initiatives [108][115]

All statements made in this release are made only as of the date set forth at the beginning of this release. We undertake no obligation to update the information made in this release in the event facts or circumstances subsequently change after the date of this release. Our audited consolidated financial statements for the year ended December 31, 2023 are not yet available. As a result, all financial results described in this earnings release should be considered preliminary, and are subject to change to re ...